NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00117598,Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL),https://clinicaltrials.gov/study/NCT00117598,OPTIMAL,COMPLETED,"This is an open-label, randomized trial in relapsed refractory subjects with mantle cell lymphoma (MCL).",YES,Lymphoma,DRUG: Temsirolimus (CCI-779)|DRUG: Temsirolimus (CCI-779)|DRUG: Investigator's choice,"Progression-Free Survival (PFS), The period from randomization until disease progression, death or date of last contact., Baseline, every 8 weeks up to Year 1, then every 12 weeks up to Year 2, and then every 6 months until tumor progression or death (up to Year 5)","Percentage of Participants With Objective Response, Assessment of complete or partial response (CR, PR) or uncomplete response (CRu) using Response Evaluation Criteria in Solid Tumors. CR: 1) No disease evident. 2) Lymph node, nodal mass regressed to normal size. 3) Previously enlarged organ ↓ size. 4) Bone marrow clear on repeat aspirate, biopsy. CRu: CR 1 and 3, at least 1 of following: Lymph node regressed \>75%. Bone marrow ↑ number or aggregate size, no cytologic/architectural atypia. PR: ≥50% ↓ index lesion, no size ↑ in other nodes, liver, spleen. Splenic and hepatic nodule regressed ≥50%. No new disease., Baseline, every 8 weeks up to Year 1, then every 12 weeks up to Year 2, and then every 6 months until tumor progression or death (up to Year 5)","Overall Survival (OS), Overall survival is the duration from randomization to death. For participants who are alive, overall survival is censored at the last contact., Baseline up to 5 years|Time to Response, Time between the date of randomization and the first date of objective response for participants with a confirmed objective response., Baseline, every 8 weeks up to Year 1, then every 12 weeks up to Year 2, and then every 6 months until tumor progression or death (up to Year 5)|Duration of Response, Time from the first documentation of objective tumor response to first date that recurrence or progressive disease (PD) was objectively documented; censored at last valid tumor assessment., Baseline, every 8 weeks up to Year 1, then every 12 weeks up to Year 2, and then every 6 months until tumor progression or death (up to Year 5)|Time to Failure (TTF), TTF is defined as the time from randomization to the date of the first documentation of Progressive Disease (PD), the date of treatment discontinuation except completion of treatment, or date of death (any cause)., Baseline, every 8 weeks up to Year 1, then every 12 weeks up to Year 2, and then every 6 months until tumor progression or death (up to Year 5)|Time to Tumor Progression (TTP), TTP: time from randomization to first documentation of objective tumor progression (including recurrence); censored at last valid tumor assessment., Baseline, every 8 weeks up to Year 1, then every 12 weeks up to Year 2, and then every 6 months until tumor progression or death (up to Year 5)",Pfizer,,ALL,"ADULT, OLDER_ADULT",PHASE3,169,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,3066K1-305,2005-05,2007-08,2011-01,2005-07-07,2012-03-06,2015-03-30,"Pfizer Investigational Site, Little Rock, Arkansas, 72205, United States|Pfizer Investigational Site, Fountain Valley, California, 92708, United States|Pfizer Investigational Site, Los Angeles, California, 90024-2828, United States|Pfizer Investigational Site, New Milford, Connecticut, 06776, United States|Pfizer Investigational Site, Washington, District of Columbia, 20007, United States|Pfizer Investigational Site, Boca Raton, Florida, 33428, United States|Pfizer Investigational Site, Honolulu, Hawaii, 96813, United States|Pfizer Investigational Site, Chicago, Illinois, 60612, United States|Pfizer Investigational Site, Morristown, New Jersey, 07960, United States|Pfizer Investigational Site, Buffalo, New York, 14263, United States|Pfizer Investigational Site, New York, New York, 10029-6574, United States|Pfizer Investigational Site, Rochester, New York, 14642-8668, United States|Pfizer Investigational Site, Portland, Oregon, 97227, United States|Pfizer Investigational Site, Upland, Pennsylvania, 19013, United States|Pfizer Investigational Site, Austin, Texas, 78705, United States|Pfizer Investigational Site, Grapevine, Texas, 76051, United States|Pfizer Investigational Site, Houston, Texas, 77030-4009, United States|Pfizer Investigational Site, Temple, Texas, 76508, United States|Pfizer Investigational Site, Seattle, Washington, 98101, United States|Pfizer Investigational Site, Buenos Aires, C1405BWU, Argentina|Pfizer Investigational Site, Buenos Aires, C1406FWZ, Argentina|Pfizer Investigational Site, Cordoba, 5000, Argentina|Pfizer Investigational Site, East Melbourne, Victoria, 3000, Australia|Pfizer Investigational Site, Wien, A-1090, Austria|Pfizer Investigational Site, Brugge, 8000, Belgium|Pfizer Investigational Site, Gent, 9000, Belgium|Pfizer Investigational Site, Leuven, 3000, Belgium|Pfizer Investigational Site, Vila Buarque, Sao Paulo, 01221-010, Brazil|Pfizer Investigational Site, Porto Alegre - RS, 90610-000, Brazil|Pfizer Investigational Site, Edmonton, Alberta, T6G 1Z2, Canada|Pfizer Investigational Site, Vancouver, British Columbia, V6Z 1Y6, Canada|Pfizer Investigational Site, London, Ontario, N6A 4L5, Canada|Pfizer Investigational Site, Ottawa, Ontario, K1H 8L6, Canada|Pfizer Investigational Site, Toronto, Ontario, M5G 2C4, Canada|Pfizer Investigational Site, Greenfield Park, Quebec, J4V 2H1, Canada|Pfizer Investigational Site, Montreal, Quebec, H1T2M4, Canada|Pfizer Investigational Site, Montreal, Quebec, H4J 1C5, Canada|Pfizer Investigational Site, Providencia, Santiago, Chile|Pfizer Investigational Site, Beijing, 100021, China|Pfizer Investigational Site, Beijing, 100036, China|Pfizer Investigational Site, Shanghai, 2000025, China|Pfizer Investigational Site, Shanghai, 200032, China|Pfizer Investigational Site, Shanghai, 200433, China|Pfizer Investigational Site, Lyon, 69008, France|Pfizer Investigational Site, Paris Cedex 15, 75747, France|Pfizer Investigational Site, Paris, 75475, France|Pfizer Investigational Site, Pierre Benite, 69495, France|Pfizer Investigational Site, Strasbourg, 67098, France|Pfizer Investigational Site, Villejuif Cedex, 94805, France|Pfizer Investigational Site, Ulm, BW, 89070, Germany|Pfizer Investigational Site, Ulm, BW, 89081, Germany|Pfizer Investigational Site, Heidelberg, 69120, Germany|Pfizer Investigational Site, Mainz, 55131, Germany|Pfizer Investigational Site, Bologna, 40128, Italy|Pfizer Investigational Site, Catania, 95124, Italy|Pfizer Investigational Site, Milano, 20132, Italy|Pfizer Investigational Site, Roma, 00161, Italy|Pfizer Investigational Site, Rotterdam, 3015 GD, Netherlands|Pfizer Investigational Site, Lublin, 20-081, Poland|Pfizer Investigational Site, Warszawa, 02-781, Poland|Pfizer Investigational Site, L'Hospitalet de Llobregat, Barcelona, 08907, Spain|Pfizer Investigational Site, Pamplona, Navarra, 31008, Spain|Pfizer Investigational Site, Barcelona, 08035, Spain|Pfizer Investigational Site, Madrid, 28006, Spain|Pfizer Investigational Site, Madrid, 28041, Spain|Pfizer Investigational Site, Lund, 221 85, Sweden|Pfizer Investigational Site, Uppsala, 751 85, Sweden|Pfizer Investigational Site, Aarau, 5001, Switzerland|Pfizer Investigational Site, Plymouth, Devon, PL6 8DH, United Kingdom|Pfizer Investigational Site, Southampton, Hants, SO16 6YD, United Kingdom|Pfizer Investigational Site, Tooting, London, SW17 0QT, United Kingdom|Pfizer Investigational Site, Sutton, Surrey, SM2 5PT, United Kingdom",
